Helen Jamet is a medical entomologist with more than 20 years of experience in malaria prevention, research, and vector control product development.
Helen joined the Bill & Melinda Gates Foundation in November 2018 as deputy director, Vector Control for the Malaria team after 11 ½ years in industry. Helen worked at Vestergaard from 2007 to 2018, where she finished as the global head of Research & Market Access. In this role, she was responsible for defining the pathway to bring new products to market, as well as developing and maintaining a healthy new product pipeline. Helen has also worked on the first next-generation long lasting insecticidal bed net since 2007.
Prior to joining Vestergaard, Helen was a consultant medical entomologist working for American Biophysics Corporation, based in Tanzania, East Africa where she built a research station and evaluated mosquito traps being developed for the African market. During that time, Helen initiated and ran a field training course for East African entomologists designed to encourage young scientists to enter into the field of entomology. She has also served as a research fellow for the London School of Hygiene & Tropical Medicine where she worked on methods of personal protection against mosquitoes for a project funded by the Bill & Melinda Gates Foundation.
Helen holds a Ph.D. in Infectious Diseases and a Master of Science in Medical Parasitology from the London School of Hygiene and Tropical Medicine. She earned a Bachelor of Science (Hons) in Applied Biology from the University of Leeds in the UK. Helen is a fellow of The Royal Society of Tropical Medicine & Hygiene and the Royal Entomological Society and has been an active member of industry groups, including the Insecticide Resistance Action Committee.
More about the foundation
Learn about where we work around the globe and the programs we've created to address urgent issues in global health, global development, and education.
Read the latest stories, research, and news from across the foundation and subscribe to our weekly newsletter, The Optimist.